TWST · Twist Bioscience Corp
Price
Snapshot
50 fields · last close| Market Cap | $9.51B |
| P/E | — |
| Float | 61.33M |
| Beta | 2.18 |
| Volatility | 54.4% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Very High |
| Clavix score | 43.8 |
| Price | 131.00 |
| Change | −1.32% |
| Prev Close | 132.75 |
| Open | 138.09 |
| Day Low | 130.68 |
| Day High | 148.32 |
| Avg Vol | 4 |
| Avg $ Vol | $535.9M |
| 52W High | 219.71 |
| 52W Low | 23.30 |
| 52W Pos | 54.8% |
| From High | −40.38% |
| From Low | +462.23% |
| Max DD 1Y | −29.52% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | −22.80% |
| SMA 50 | −11.15% |
| SMA 200 | +58.30% |
| RSI (14) | 43.0 |
| Vol 30D | 96.7% |
| Vol 90D | 90.5% |
| 1Y Range | 23–220 |
| Daily bars | 535 |
| Perf Week | −4.97% |
| Perf Month | +0.99% |
| Perf Quarter | +53.96% |
| Perf Half Y | +156.96% |
| Perf Year | +372.96% |
| Perf YTD | +304.45% |
| Prev Day | −1.32% |
| Clavix | D+ |
| Debt / Eq | 0.01 |
| Curr Ratio | 3.64 |
| Int Cover | -801.0× |
| FCF Margin | — |
| Rev Growth | +20.3% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 30 / 35 |
Clavix risk grade
regraded every trading dayTWST grades D+, 43.8 of 100. Steadiest on News Sentiment (67), most exposed on Price Stability (22, weak). 0 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 30 of 35 in Biotechnology by Clavix score.
How rough the ride is
| TWST | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 2.18 | 0.50 |
| Volatilityannualized | 54.4% | 14.4% |
| Max drawdown, past yearworst peak-to-trough fall | −29.5% | — |
| Typical daily movemedian absolute daily change | 3.04% | — |
| Days beyond ±3%of the last 252 sessions | 128 (51%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| TWST | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 2.18 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Very High | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| TWST | |
|---|---|
| 1 week | −5.0% |
| 1 month | +1.0% |
| Year to date | +304.4% |
| 1 year | +373.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| TWST | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 14 Jul |
| Average score0 most bearish, 100 most bullish | 59 |
| Bullish · bearisharticles above 60 · below 40 | 18 · 9 |
| Directionarticles whose tone is improving vs worsening | 18 ↑ 9 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| TWST | |
|---|---|
| Revenue growthyear over year | +20.3% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openThe article highlights three stocks outperforming the 'Magnificent Seven' this year, mentioning Moderna (boosted by personalized cancer vaccine results) and Twist Bioscience (seeing strong demand for its synthetic DNA). The body is too short to extract further detail.
Twist Bioscience CEO Emily Leproust sold 5,203 shares of company stock on September 24th at an average price of $177.38 per share, for total proceeds of $922,908.14. After the sale, she directly owns 613,699 shares.
Twist Bioscience CEO Emily Leproust sold 1,687 shares on September 21st at an average price of $165.49, totaling about $279,182. After the sale she still holds 618,902 shares in the company.
Twist Bioscience's stock rose 16% on Thursday, September 24, after Leerink Partners called the company the single most important beneficiary of Anthropic's expanding biology research. TIKR tracks 13 analysts covering the stock: 7 buys, 2 outperforms, 3 holds, and 1 sell.
Twist Bioscience (TWST) has added its antibody characterization platform (technology that tests and profiles antibodies, the proteins used in many medicines) to Lilly TuneLab, an AI and machine learning drug discovery hub built around Eli Lilly's research data and partner biotech companies. The article notes TWST shares have returned 80.19% over 90 days and 408.18% year to date, with a one-year total shareholder return of roughly 5x, closing the latest session at $164.60 (down 0.74%).
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| KRYS | Krystal Biotech Inc | B | $9.77B | 40.85 | 0.65 | Compare |
| CAI | Caris Life Sciences Inc | C | $8.98B | 85.37 | 0.40 | Compare |
| CYTK | Cytokinetics Inc | B+ | $8.89B | — | 0.42 | Compare |
| SYRE | Spyre Therapeutics Inc | — | $8.87B | — | 2.95 | Compare |
| PTGX | Protagonist Therapeutics Inc | B | $8.84B | 107.21 | 1.19 | Compare |
| TGTX | TG Therapeutics Inc | B- | $8.57B | 18.85 | 1.82 | Compare |
| MDGL | Madrigal Pharmaceuticals Inc | B | $10.62B | — | -1.08 | Compare |
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $8.26B | — | 1.34 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.